YR001 Phase IIa Clinical Study Topline results

Baseline Demographics & Disease Characteristics

Mean age: 43.4 years (range 18–75)
Sex: 62.9% female
Race/Ethnicity: 54.3% White; 51.4% non-Hispanic/Latino
All diagnosed with AD
Baseline ISGA:
-Mild: 51.4% (18/35)
-Moderate: 48.6% (17/35)
Allergic history: 77.1% (27/35) had no history of allergies
Substance/alcohol/smoking: None; 97.1% had no recent smoking history
Overall: No notable between-group differences in baseline demographic or disease characteristics

Clinical Results Summary

• ISGA: After treatment administration, the proportion of subjects in the YR001 group achieving an ISGA score of 0 or 1 was more than three times that of the placebo group（23.1% vs. 7.1%）.

• EASI: After treatment administration, the proportion of subjects achieving EASI-50 in the YR001 group was more than 10 percentage points higher than that in the placebo group（46.2% vs. 35.7%). Notably, at the lower extremity sites, the YR001 group showed a significant treatment benefit at the end of the trial (P < 0.05).

•PP-NRS: After treatment administration, the proportion of subjects achieving a “clinically meaningful improvement” (an absolute NRS improvement of ≥ 4) in the YR001 group was more than twice that of the placebo group.

• DLQI: After treatment administration, there was a marked difference in treatment effects between the two groups, particularly in the improvement of impact on social and leisure activities, where the YR001 group showed significantly better results (P < 0.05).

•YR001 also demonstrated a favorable safety profile: NO treatment-related adverse events occurred in any dosed subject during the treatment period.

• NanoString analysis of skin-biopsy samples suggested that the YR001 responder phenotype involves a shift from a baseline state characterized by elevated inflammatory and cytokine-driven signaling, including Type 2 and Th17/Th22 pathways, toward a post-treatment state marked by reduced Type 2/lymphoid and TNF/NF-kB signaling, together with enhanced tissue-repair processes.